Price Alert

Sage Therapeutics Inc. (SAGE)

NASDAQ: SAGE · Real-Time Price · USD

8.68

0.00 (0.00%)

At close: Jul 30, 2025, 3:59 PM

0.00% (1D)

Bid	8.67
Market Cap	544.94M
Revenue (ttm)	70.41M
Net Income (ttm)	-301.19M
EPS (ttm)	-4.89
PE Ratio (ttm)	-1.7750511247443763
Forward PE	-3.21
Analyst	Hold

Ask	8.8
Volume	17,394,354
Avg. Volume (20D)	2,480,352
Open	8.68
Previous Close	8.68
Day's Range	8.68 - 8.68
52-Week Range	4.62 - 9.36
Beta	0.30

About SAGE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol SAGE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for SAGE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Sage Therapeutics has released their quartely earnings on Jul 30, 2025:

Revenue of $31.66M exceeds estimates by $14.62M, with 265.84% YoY growth.

EPS of -0.79 exceeds estimates by 0.16, with 53.53% YoY growth.

Next Earnings Release

Sage Therapeutics Inc. is scheduled to release its earnings on Oct 28, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+35.37%

Sage Therapeutics shares are trading higher after ... Unlock content with Pro Subscription

7 months ago

+35.14%

Sage Therapeutics shares are trading higher after the company confirmed the receipt of an unsolicited, nonbinding proposal from Biogen to acquire all outstanding shares not already owned by Biogen for $7.22 per share.

News

1 month ago · zacks.com

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

Sage Therapeutics, Inc. (SAGE) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $1.7 per share a year ago.

1 month ago · businesswire.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage ...

2 months ago · zacks.com

What Makes Sage Therapeutics (SAGE) a New Buy Stock

Sage Therapeutics (SAGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

2 months ago · benzinga.com

These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News

Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.

2 months ago · zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength do...

2 months ago · accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the Company") ...

2 months ago · businesswire.com

SAGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sage Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage ...

2 months ago · barrons.com

Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know.

The deal is worth an initial $561 million, with potential for $234 million in add-ons.

2 months ago · businesswire.com

Shareholder Alert: The Ademi Firm Investigates Whether Sage Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Sage (NASDAQ: SAGE) for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus Pharmaceuticals. Cl...

Load More News